Ole Schjerning1,2,3, Mary Rosenzweig4, Anton Pottegård5, Per Damkier5,6, Jimmi Nielsen7,8. 1. Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark. o.schjerning@rn.dk. 2. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. o.schjerning@rn.dk. 3. Centre for Schizophrenia, Brandevej 5, 9220, Aalborg, Denmark. o.schjerning@rn.dk. 4. Danish Health and Medicines Authority, Copenhagen, Denmark. 5. Clinical Pharmacology, Department of Public Health, University of Southern Denmark, Odense, Denmark. 6. Department of Clinical Chemistry and Pharmacology, Odense University Hospital, Odense, Denmark. 7. Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark. 8. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Abstract
BACKGROUND: Several case reports and epidemiological studies have raised concern about the abuse potential of pregabalin, the use of which has increased substantially over the last decade. Pregabalin is, in some cases, used for recreational purposes and it has incurred attention among drug abusers for causing euphoric and dissociative effects when taken in doses exceeding normal therapeutic dosages or used by alternative routes of administration, such as nasal insufflation or venous injection. The magnitude of the abuse potential and the mechanism behind it are not fully known. OBJECTIVE: The aim of this study was to present a systematic review of the data concerning the abuse potential of pregabalin. METHODS: We performed a systematic literature search and reviewed the preclinical, clinical and epidemiological data on the abuse potential of pregabalin. RESULTS: We included preclinical (n = 17), clinical (n = 19) and epidemiological (n = 13) studies addressing the abuse potential of pregabalin. We also reviewed case reports (n = 9) concerning abuse of pregabalin. The preclinical studies indicated that pregabalin possesses modulatory effects on the GABA and glutamate systems, leaving room for an abuse potential. Further, clinical studies reported euphoria as a frequent side effect in patients treated with pregabalin. The majority of case reports concerning abuse of pregabalin involved patients with a history of substance abuse and, similarly, epidemiological studies found evidence of abuse, especially among opiate abusers. CONCLUSIONS: Overall, the available literature suggests an important clinical abuse potential of pregabalin and prescribers should pay attention to signs of abuse, especially in patients with a history of substance abuse.
BACKGROUND: Several case reports and epidemiological studies have raised concern about the abuse potential of pregabalin, the use of which has increased substantially over the last decade. Pregabalin is, in some cases, used for recreational purposes and it has incurred attention among drug abusers for causing euphoric and dissociative effects when taken in doses exceeding normal therapeutic dosages or used by alternative routes of administration, such as nasal insufflation or venous injection. The magnitude of the abuse potential and the mechanism behind it are not fully known. OBJECTIVE: The aim of this study was to present a systematic review of the data concerning the abuse potential of pregabalin. METHODS: We performed a systematic literature search and reviewed the preclinical, clinical and epidemiological data on the abuse potential of pregabalin. RESULTS: We included preclinical (n = 17), clinical (n = 19) and epidemiological (n = 13) studies addressing the abuse potential of pregabalin. We also reviewed case reports (n = 9) concerning abuse of pregabalin. The preclinical studies indicated that pregabalin possesses modulatory effects on the GABA and glutamate systems, leaving room for an abuse potential. Further, clinical studies reported euphoria as a frequent side effect in patients treated with pregabalin. The majority of case reports concerning abuse of pregabalin involved patients with a history of substance abuse and, similarly, epidemiological studies found evidence of abuse, especially among opiate abusers. CONCLUSIONS: Overall, the available literature suggests an important clinical abuse potential of pregabalin and prescribers should pay attention to signs of abuse, especially in patients with a history of substance abuse.
Authors: Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger Journal: Clin Pharmacokinet Date: 2010-10 Impact factor: 6.447
Authors: Søren Schou Olesen; Stefan A W Bouwense; Oliver H G Wilder-Smith; Harry van Goor; Asbjørn Mohr Drewes Journal: Gastroenterology Date: 2011-04-14 Impact factor: 22.682
Authors: Atul C Pande; Jerri G Crockatt; Douglas E Feltner; Carol A Janney; Ward T Smith; Richard Weisler; Peter D Londborg; Robert J Bielski; Dan L Zimbroff; Jonathan R T Davidson; Maria Liu-Dumaw Journal: Am J Psychiatry Date: 2003-03 Impact factor: 18.112
Authors: Lesley M Arnold; I Jon Russell; E W Diri; W Rachel Duan; James P Young; Uma Sharma; Susan A Martin; Jeannette A Barrett; George Haig Journal: J Pain Date: 2008-06-03 Impact factor: 5.820
Authors: Thitiporn Supasitthumrong; Blanca M Bolea-Alamanac; Selim Asmer; Vincent L Woo; Petal S Abdool; Simon J C Davies Journal: Br J Clin Pharmacol Date: 2019-02-08 Impact factor: 4.335